Financials

Company Profile

November 26, Inc., formerly BIOLASE, Inc., is not engaged in any business activities. The Company has no assets.

Employees

157

Sector

Market Closed - OTC Markets 13:49:28 2026-04-16 EDT			5-day change	1st Jan Change
0.000100 ^USD	-.--%		+9,900.00%	+9,900.00%

25-08-26	MegaGen Implant Co., Ltd. acquired All Assets of BIOLASE, Inc from BIOLASE, Inc. (OTCPK:BIOL.Q).	CI
25-05-19	EnVVeno Medical Names Jennifer Bright CFO	MT

25-08-26	MegaGen Implant Co., Ltd. acquired All Assets of BIOLASE, Inc from BIOLASE, Inc. (OTCPK:BIOL.Q).	CI
25-05-19	EnVVeno Medical Names Jennifer Bright CFO	MT
25-03-04	Motion for Asset Sale Approved for BIOLASE, Inc.	CI
25-02-24	Second Amended Combined Liquidation Plan & Disclosure Approved for BIOLASE, Inc.	CI
25-02-20	Second Amended Combined Liquidation Plan & Disclosure Statement Filed by BIOLASE, Inc.	CI
25-02-17	Motion for Exclusivity Period Extension Approved For BIOLASE, Inc.	CI
25-02-13	Motion for Asset Sale Filed by BIOLASE, Inc.	CI
25-01-28	First Motion for Exclusivity Period Extension Filed by BIOLASE, Inc.	CI
25-01-13	First Amended Disclosure Statement Approved on Interim Basis for BIOLASE, Inc.	CI
25-01-13	First Amended Combined Liquidation Plan and Disclosure Statement Filed by BIOLASE, Inc.	CI
25-01-07	Disclosure Statement Conditionally Approved for BIOLASE, Inc.	CI
24-12-22	Combined Liquidation Plan and Disclosure Statement Filed by BIOLASE, Inc.	CI
24-11-14	Motion for Asset Sale Approved for BIOLASE, Inc.	CI

24-04-01	Ascendiant Capital Adjusts Biolase's Price Target to $4 From $15, Reiterates Buy Rating	MT
23-05-31	Lake Street Adjusts Price Target on Biolase to $0.40 From $1.50, Maintains Buy Rating	MT
23-01-20	Lake Street Assumes Biolase at Buy With $1.50 Price Target	MT
22-05-20	Lake Street Initiates Biolase at Buy, Sets Price Target at $12	MT

25-10-14	BIOLASE Showcases Breakthrough YSGG Laser Protocol for Predictable Periodontitis Treatment at AAP 2025	PR
24-11-08	Biolase: Q3 Earnings Snapshot	AQ
24-11-07	BIOLASE : Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)	PU
24-10-01	BIOLASE : Voluntarily Initiates Chapter 11 Proceedings Form 8 K	PU
24-08-08	Biolase: Q2 Earnings Snapshot	AQ

Manager	Title	Age	Since
Gwang-Bum Park CEO	Chief Executive Officer	65	2025-09-09
Steven Sandor COO	Chief Operating Officer	46	2022-07-05
Samuel B. Low CTO	Chief Tech/Sci/R&D Officer	-	2016-09-30

Director	Title	Age	Since
Jonathan Lord CHM	Chairman	71	2017-08-31
Kathleen O'Loughlin BRD	Director/Board Member	75	2021-08-15
Martha Somerman BRD	Director/Board Member	-	2021-08-15

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/28/23	Goldman Sachs & Co. LLC (Private Banking)	Other	Company	144,501	13.8444%
6/8/23	Jonathan Lord	Free	Chairman	721,154	2.3039%
6/8/23	Kathleen O'Loughlin	Free	Director	502,404	1.6050%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOLASE, INC.	-.--%	+9,900.00%	-.--%	-100.00%	36
CHURCHILL CAPITAL CORP XI	-1.10%	+1.63%	-	-	912M
CENTIEL AG	+5.20%	+1.47%	+316.97%	-69.29%	658M
CHURCHILL CAPITAL CORP XII	-0.19%	+0.05%	-	-	603M
BAIN CAPITAL GSS INVESTMENT CORP.	-0.10%	+0.29%	-	-	599M
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	-0.26%	+0.61%	-	-	575M
NEW AMERICA ACQUISITION I CORP.	-0.15%	+0.26%	-	-	507M
CHURCHILL CAPITAL CORP XIII	+1.01%	+0.77%	-	-	504M
ARES ACQUISITION CORPORATION III	-0.88%	-0.35%	-	-	490M
Average	+0.39%	+0.57%	+158.48%	-84.64%	538.68M
Weighted average by Cap.	+0.43%	+0.75%	+316.97%	-69.29%